Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.

Gyori D, Lim EL, Grant FM, Spensberger D, Roychoudhuri R, Shuttleworth SJ, Okkenhaug K, Stephens LR, Hawkins PT.

JCI Insight. 2018 Jun 7;3(11). pii: 120631. doi: 10.1172/jci.insight.120631. eCollection 2018 Jun 7.

2.

Functional characterization of a novel somatic oncogenic mutation of PIK3CB.

Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ.

Signal Transduct Target Ther. 2017 Dec 22;2:17063. doi: 10.1038/sigtrans.2017.63. eCollection 2017.

3.

Science Periodicals in the Nineteenth and Twenty-First Centuries.

Shuttleworth S, Charnley B.

Notes Rec R Soc Lond. 2016 Dec 20;70(4):297-304. No abstract available.

4.

Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation.

Ellis JD, Neil DA, Inston NG, Jenkinson E, Drayson MT, Hampson P, Shuttleworth SJ, Ready AR, Cobbold M.

Transplantation. 2016 Aug;100(8):1667-74. doi: 10.1097/TP.0000000000001208.

PMID:
27222932
5.

Randomized controlled trial of computerized alcohol intervention for college students: role of class level.

Strohman AS, Braje SE, Alhassoon OM, Shuttleworth S, Van Slyke J, Gandy S.

Am J Drug Alcohol Abuse. 2016;42(1):15-24. doi: 10.3109/00952990.2015.1105241. Epub 2015 Dec 18.

PMID:
26684960
6.

Constructing Scientific Communities: Citizen Science.

Shuttleworth S, Frampton S.

Lancet. 2015 Jun 27;385(9987):2568. doi: 10.1016/S0140-6736(15)61150-3. No abstract available.

PMID:
26122151
7.

Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.

Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, Goldstein DM, Hancox T, Kaur J, Knowles D, Kondru R, Lesnick J, Lucas MC, Lewis C, Murray J, Nadin AJ, Nonomiya J, Pang J, Pegg N, Price S, Reif K, Safina BS, Salphati L, Staben S, Seward EM, Shuttleworth S, Sohal S, Sweeney ZK, Ultsch M, Waszkowycz B, Wei B.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4296-302. doi: 10.1016/j.bmcl.2012.05.027. Epub 2012 May 17.

PMID:
22672799
8.

Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.

Safina BS, Baker S, Baumgardner M, Blaney PM, Chan BK, Chen YH, Cartwright MW, Castanedo G, Chabot C, Cheguillaume AJ, Goldsmith P, Goldstein DM, Goyal B, Hancox T, Handa RK, Iyer PS, Kaur J, Kondru R, Kenny JR, Krintel SL, Li J, Lesnick J, Lucas MC, Lewis C, Mukadam S, Murray J, Nadin AJ, Nonomiya J, Padilla F, Palmer WS, Pang J, Pegg N, Price S, Reif K, Salphati L, Savy PA, Seward EM, Shuttleworth S, Sohal S, Sweeney ZK, Tay S, Tivitmahaisoon P, Waszkowycz B, Wei B, Yue Q, Zhang C, Sutherlin DP.

J Med Chem. 2012 Jun 28;55(12):5887-900. doi: 10.1021/jm3003747. Epub 2012 Jun 11.

PMID:
22626259
9.

Victorian visions of child development.

Shuttleworth S.

Lancet. 2012 Jan 21;379(9812):212-3. No abstract available.

PMID:
22272394
10.

AMG 837: a potent, orally bioavailable GPR40 agonist.

Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, Sharma R, Schmitt M, Wang Y, Liu J, Liu J, Medina JC, Reagan JD, Luo J, Tonn G, Zhang J, Lu JY, Chen M, Lopez E, Nguyen K, Yang L, Tang L, Tian H, Shuttleworth SJ, Lin DC.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1267-70. doi: 10.1016/j.bmcl.2011.10.118. Epub 2011 Nov 6.

PMID:
22217876
11.

Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.

Heffron TP, Wei B, Olivero A, Staben ST, Tsui V, Do S, Dotson J, Folkes AJ, Goldsmith P, Goldsmith R, Gunzner J, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Shuttleworth S, Sutherlin DP, Wan NC, Wang S, Wiesmann C, Zhu BY.

J Med Chem. 2011 Nov 24;54(22):7815-33. doi: 10.1021/jm2007084. Epub 2011 Oct 21.

PMID:
21985639
12.

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P.

Curr Med Chem. 2011;18(18):2686-714. Review.

13.

Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.

Shuttleworth S, Townsend P, Silva F, Cecil A, Hill T, Tomassi C, Rogers H, Harrison R.

Prog Med Chem. 2011;50:109-33. doi: 10.1016/B978-0-12-381290-2.00003-3. No abstract available.

PMID:
21315929
14.

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements.

Large JM, Torr JE, Raynaud FI, Clarke PA, Hayes A, Stefano Fd, Urban F, Shuttleworth SJ, Saghir N, Sheldrake P, Workman P, McDonald E.

Bioorg Med Chem. 2011 Jan 15;19(2):836-51. doi: 10.1016/j.bmc.2010.12.006. Epub 2010 Dec 9.

PMID:
21216151
15.

Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.

Shuttleworth SJ, Bailey SG, Townsend PA.

Curr Drug Targets. 2010 Nov;11(11):1430-8. Review.

PMID:
20583972
16.

Homology modelling of Drosophila cytochrome P450 enzymes associated with insecticide resistance.

Jones RT, Bakker SE, Stone D, Shuttleworth SN, Boundy S, McCart C, Daborn PJ, ffrench-Constant RH, van den Elsen JM.

Pest Manag Sci. 2010 Oct;66(10):1106-15. doi: 10.1002/ps.1986.

PMID:
20583201
17.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.

Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P.

Mol Cancer Ther. 2009 Jul;8(7):1725-38. doi: 10.1158/1535-7163.MCT-08-1200. Epub 2009 Jul 7.

18.

Discovery and optimization of a novel Neuromedin B receptor antagonist.

Fu J, Shuttleworth SJ, Connors RV, Chai A, Coward P.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4264-7. doi: 10.1016/j.bmcl.2009.05.124. Epub 2009 Jun 6.

PMID:
19553112
19.

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P.

Prog Med Chem. 2009;48:81-131. Review. No abstract available.

PMID:
21544958
20.

RCVS modular CertAVP and ophthalmology.

Manning P, Shuttleworth S, Whipp C, Duncanson G.

Vet Rec. 2008 Nov 1;163(18):549. No abstract available.

PMID:
18978371
21.

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ.

J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.

PMID:
18754654
22.

Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.

Zvelebil MJ, Waterfield MD, Shuttleworth SJ.

Arch Biochem Biophys. 2008 Sep 15;477(2):404-10. doi: 10.1016/j.abb.2008.06.024. Epub 2008 Jul 8.

PMID:
18647592
23.

Exploring the specificity of the PI3K family inhibitor LY294002.

Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD.

Biochem J. 2007 May 15;404(1):15-21.

24.

SPVS Group.

Manning P, Viner B, Duncanson G, Whipp C, Shuttleworth S.

J Small Anim Pract. 2006 Jul;47(7):416. No abstract available.

PMID:
16842283
25.

Mosaicism of proximal 15q duplication/deletion resulting in Prader-Willi syndrome with normal methylation.

Boyd L, Brown MG, Kelson S, Lawce H, Shuttleworth S, Unsworth N, Magenis RE.

Am J Med Genet A. 2005 Oct 1;138A(2):181-4. No abstract available.

PMID:
16100727
26.

Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization.

Shuttleworth SJ, Connors RV, Fu J, Liu J, Lizarzaburu ME, Qiu W, Sharma R, Wãnska M, Zhang AJ.

Curr Med Chem. 2005;12(11):1239-81. Review.

PMID:
15974996
27.

Identification and optimization of novel partial agonists of neuromedin B receptor using parallel synthesis.

Shuttleworth SJ, Lizarzaburu ME, Chai A, Coward P.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3037-42.

PMID:
15149640
28.

Certificates in general practice.

Manning P, Viner B, Shuttleworth S, Whipp C, Muckle A, Posnett S, Duncanson G, Boness J.

Vet Rec. 2003 Jun 7;152(23):723. No abstract available.

PMID:
12825709
29.

Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome.

Kenwrick S, Woffendin H, Jakins T, Shuttleworth SG, Mayer E, Greenhalgh L, Whittaker J, Rugolotto S, Bardaro T, Esposito T, D'Urso M, Soli F, Turco A, Smahi A, Hamel-Teillac D, Lyonnet S, Bonnefont JP, Munnich A, Aradhya S, Kashork CD, Shaffer LG, Nelson DL, Levy M, Lewis RA; International IP Consortium.

Am J Hum Genet. 2001 Dec;69(6):1210-7. Epub 2001 Oct 22.

30.
31.

Parallel synthesis of isatin-based serine protease inhibitors.

Shuttleworth SJ, Nasturica D, Gervais C, Siddiqui MA, Rando RF, Lee N.

Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.

PMID:
11086715
32.

Parallel solution synthesis of pyridinethiones, pyridinones and thienopyridines.

Shuttleworth SJ, Quimpère M, Lee N, DeLuca J.

Mol Divers. 1998;4(3):183-5.

PMID:
10729903
33.

Violence to staff in a general hospital setting.

Whittington R, Shuttleworth S, Hill L.

J Adv Nurs. 1996 Aug;24(2):326-33.

PMID:
8858437
34.

A caring approach.

Beer D, Stowers A, Shuttleworth S.

Community Outlook. 1979 Aug 9:232. No abstract available.

PMID:
256809

Supplemental Content

Loading ...
Support Center